Sarepta (SRPT) insider grants 143,875 RSUs to President of R&D; vesting through 2028

Rhea-AI Filing Summary

Louise Rodino-Klapac, President of R&D and Tech Ops at Sarepta Therapeutics (SRPT), reported insider acquisitions on Form 4. On 09/03/2025 she was granted two awards of restricted stock units (RSUs): 93,875 RSUs that vest 50% on 09/03/2026 and 50% on 09/03/2027, and 50,000 performance-based RSUs that vest 100% on 09/03/2028 subject to service and achievement of performance criteria. The transactions were reported as acquisitions at $0 per share because they are equity awards. Following the grants and an earlier purchase of 106 shares on 08/31/2025 under the ESPP, she beneficially owned 228,612 shares after the reported transactions.

Positive

• Significant retention and alignment: 143,875 RSUs granted with staggered vesting aligns executive incentives with long-term company performance
• Performance component included: 50,000 RSUs vest only upon achievement of performance criteria, linking pay to outcomes
• Insider ownership increased: Beneficial ownership rose to 228,612 shares, showing continued insider stake in SRPT

Negative

• No immediate liquidity: RSUs vest over 2026-2028, so they do not provide short-term share increases to the market but will if/when vested
• Potential future dilution: Issuance of shares upon vesting will increase share count, though the filing does not quantify dilution impact

Insights

Financial Analyst

TL;DR: Executive received large multi-year RSU grants consistent with retention and performance incentives; no cash sale or dilution event reported.

The grants total 143,875 RSUs, structured with time- and performance-based vesting across 2026-2028. This aligns compensation with multi-year R&D timelines and reduces near-term selling pressure because shares vest over years. There is no record of stock sales or option exercises, and the reported $0 price reflects standard equity compensation accounting rather than a market purchase. Impact on outstanding share count is indirect and occurs upon vesting and issuance of shares.

Corporate Governance Expert

TL;DR: Compensation appears customary for a senior R&D officer, combining retention and performance conditions.

The combination of time-based and performance-based RSUs suggests the Compensation Committee is tying pay to long-term milestones. Vesting schedules (50/50 time-based and a separate performance tranche) are typical for senior scientific leaders to align incentives with product development outcomes. No red flags such as accelerated vesting or immediate transfers are disclosed in the filing.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Rodino-Klapac Louise

Role President, R&D and Tech Ops

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	93,875	$0.00	--
Grant/Award	Common Stock	50,000	$0.00	--

Holdings After Transaction: Common Stock — 178,612 shares (Direct)

Footnotes (1)

1. The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 50% of the RSUs will vest on September 3, 2026, and the remaining 50% will vest on September 3, 2027, subject to the Reporting Person's continued service to the Company. Includes 106 shares of common stock purchased on August 31, 2025 through the Company's Employee Stock Purchase Plan The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 100% of the RSUs will vest on September 3, 2028, subject to the Reporting Person's continued service to the Company and only if certain performance criteria has been deemed achieved by the Compensation Committee of the Board.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rodino-Klapac Louise

(Last) (First) (Middle)

215 FIRST STREET

SUITE 415

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sarepta Therapeutics, Inc. [ SRPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, R&D and Tech Ops

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/03/2025		A		93,875(1)	A	$0	178,612(2)	D
Common Stock	09/03/2025		A		50,000(3)	A	$0	228,612	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 50% of the RSUs will vest on September 3, 2026, and the remaining 50% will vest on September 3, 2027, subject to the Reporting Person's continued service to the Company.

2. Includes 106 shares of common stock purchased on August 31, 2025 through the Company's Employee Stock Purchase Plan

3. The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 100% of the RSUs will vest on September 3, 2028, subject to the Reporting Person's continued service to the Company and only if certain performance criteria has been deemed achieved by the Compensation Committee of the Board.

	/s/ Cristin Rothfuss, as Attorney-in-Fact for Louise Rodino-Klapac	09/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Louise Rodino-Klapac report on Form 4 for SRPT?

She reported two RSU grants (93,875 and 50,000 RSUs) on 09/03/2025 and an earlier ESPP purchase of 106 shares, resulting in 228,612 shares beneficially owned.

When do the RSUs vest for the 93,875 grant?

Fifty percent vest on 09/03/2026 and the remaining fifty percent on 09/03/2027, subject to continued service.

What are the conditions for the 50,000 performance RSUs?

They vest 100% on 09/03/2028 subject to continued service and approval by the Compensation Committee that performance criteria were achieved.

Was there any cash purchase reported in this Form 4?

Yes, 106 shares were purchased on 08/31/2025 through the company ESPP; the RSU grants are reported at $0 because they are equity awards.

Does this filing indicate any stock sales by the reporting person?

No stock sales were reported in this Form 4; all reported transactions are acquisitions or grants.